ELRIG Drug Discovery 2016 Scientific Conference Directors Announced

The ELRIG annual conference celebrates its 10 year anniversary

27 Jul 2016
Weylan Kiam-Laine
Microbiologist

Industry news

ELRIG (European Laboratory Research & Innovation Group) announced today that two new Scientific Advisors have joined the committee to help organize the UK’s largest and most successful Drug Discovery conference, which will take place at ACC, Liverpool on 13th and 14th of October 2016.

“This is a very special year in that we are celebrating our 10 year anniversary of successfully running this meeting,” said Sanj Kumar, Chairman, ELRIG. “To ensure we continue to provide cutting edge scientific content to our 7,000 strong community, we are honored to welcome two new members to the Scientific Committee: Dr Chas Bountra, Professor of Translational Medicine, University of Oxford and Head of the Structural Genomic Consortium in Oxford, and Rachel Grimley, Director of Screening Sciences at AstraZeneca.”

Dr Del Trezise, Director and European Site Head, Essen Bioscience, and leader of the scientific committee, commented: “I am delighted to be working with both Rachel and Chas. They both bring a wealth of experience and contacts within the academic and drug discovery community which will ensure that we provide the best scientific content we can across the most cutting edge areas of early drug discovery.”

Drug Discovery is the UK’s leading conference and networking event for scientific researchers and business people involved in the science of drug discovery. ELRIG has hosted this event successfully in a variety of locations, but for this special 10th anniversary year, the event returns to a favorite venue at ACC in Liverpool.

“Del, Rachel and Chas are talented and knowledgeable leaders of the drug discovery industry,” said Dr Liz Quinn, Scientific Director of ELRIG. “Their experience and strong scientific credibility has allowed us to create a strong scientific programme that showcases innovative technologies and new emerging cellular approaches that can be used to overcome drug development challenges. Providing such breadth and depth of science will make DD16 an unmissable event for all drug discovery scientists and suppliers who wish to promote their latest technologies to this market place and network with colleagues across the industry.”

Drug Discovery 2016 is free to attend for delegates, and over the two day event ELRIG will host over 1,000 delegates, 50 speakers in the 6 track scientific programme, 100 exhibitors and a poster display. New to this year’s agenda there will also be a series of core technologies workshops and vendor tutorials.

Links

Tags

AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.ProteomicsProteomics is the systemic bioinformatics study of proteins and amino acids, including their structure, size, function and identification. Tools used in proteomics include chromatography, blotting and gels, protein arrays, mass spectrometry and ELISA and associated analysis software. Analyzers and proteomic systems should be sensitive, high resolution, fast and may be automated for high-throughput.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Bioprocessing / FermentationBioprocessing is the use of biological materials to perform commercial, scientific or medical research processes. Biological materials used include cells, enzymes and organisms. Usually bioprocessing requires a batch or continuous bioreactor such as a fermentor or cell culture system. The advantages of using a reactor include high productivity, easy configuration, adjustable values and automation.Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.ELRIG